What Spatial Transcriptomics does

Spatial Transcriptomics operates as a brand and trademark of 10x Genomics, Inc., a life science tools company headquartered in Pleasanton, California. The company provides spatial transcriptomics and single cell analysis platforms that enable researchers to perform RNA sequencing with preserved two-dimensional tissue context, addressing the loss of spatial information inherent to traditional bulk and dissociated single cell methods. Core technology comprises four platforms: Visium Spatial (whole-transcriptome spatial discovery using probe-based or 3' poly(A) chemistries on a 2 μm x 2 μm barcoded slide architecture), Xenium In Situ (high-resolution single cell spatial imaging with sub-30 nm XY transcript localization precision and up to 5,000-gene customizable panels), Atera In Situ (scalable whole-transcriptome spatial profiling at subcellular resolution with up to 800 samples per year), and Chromium Single Cell (multiomic single cell processing at scale). Supporting software includes Cell Ranger, Space Ranger, and Loupe, with 10x Genomics Cloud providing instrument connectivity and data analysis. The patented stack is sold for research use only across human, mouse, rat, and other species using FFPE, fresh frozen, and fixed frozen samples.

The company monetizes through a razor-and-blade model: instrument sales (Visium CytAssist, Xenium Analyzer, Atera Instrument, Chromium instruments), high-margin recurring consumables (probe panels, microfluidic cartridges, reagent kits), subscription-style software licenses (Loupe, Cell Ranger, Space Ranger), and professional services such as Premium Automation Enablement. Distribution combines direct enterprise field sales with a global authorized distributor network; pricing is quote-based with multi-year contracts, and products are explicitly labeled for research use only. End customers are segmented across Pharma & Biotech (drug development, biomarker discovery, clinical trial optimization), Oncology Research (tumor microenvironment, immune cell mapping), Immunology (immune cell characterization and immunotherapy development), and AI & Computational Biology (training AI cell models and virtual cell development), supported by a scientific community of over 10,000 publications citing the technology. Founders Jonas Frisén and Patrik Ståhl are credited as originators of the spatial barcoding approach underlying the portfolio.

Note on data scope: the firmographic record (1-10 employees, Stockholm, founded 2016) describes the original Swedish Spatial Transcriptomics entity, while the operational data reflects 10x Genomics, Inc., the acquirer and current owner of the Spatial Transcriptomics trademark. This analysis treats the company as the operating entity represented by the operational data.

Name

Spatial Transcriptomics

Legal name

10x Genomics, Inc.

Website

https://spatialtranscriptomics.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Spatial Transcriptomics, a brand of 10x Genomics, Inc., provides spatial transcriptomics and single cell analysis platforms (Visium, Xenium, Atera, Chromium) that enable researchers to perform 2D RNA sequencing across FFPE and fresh frozen tissue, serving pharma, biotech, oncology, immunology, and AI/computational biology customers worldwide via enterprise field sales and a global distributor network.

Ownership category

akta.pro rank

Product category

Spatial Transcriptomics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

akta.pro secondary industries

Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

Keywords

• Spatial transcriptomics
• Single cell analysis
• In situ imaging
• RNA sequencing platforms
• Multiomics genomics

Headquarters

HQ city

Stockholm

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Instrument Sales: Sale of 10x branded instruments including Visium CytAssist, Xenium Analyzer, Atera Instrument, and Chromium instruments along with associated accessories.
2. Consumables: Sale of 10x reagents, microfluidic cartridges, reagent kits, and labware intended for single use with 10x Instruments. Products include probe-based and 3' poly(A) capture-based assays.
3. Software Licenses: Licensing of 10x software including Loupe Software, Cell Ranger, Space Ranger, and other data analysis software for genomic assembly, phasing, cell analysis and visualization.
4. Premium Automation Enablement Services: Automation enablement services to enable and validate third party automation platforms applied to 10x workflows, including consultation and execution support.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Spatial Transcriptomics provides spatial transcriptomics technology that allows researchers to perform RNA sequencing in 2D. The offering spans proprietary platforms including Visium HD Spatial Assays (2 μm x 2 μm barcoded squares), Xenium Analyzer (single cell spatial imaging with nanometer-level localization precision), Atera In Situ (scalable whole transcriptome spatial at subcellular resolution with up to 800 samples per year), and Chromium Single Cell, supported by bioinformatics software (Loupe, Cell Ranger, Space Ranger) and consumables for FFPE, fresh frozen, and fixed frozen tissue samples.

Product overview

10x Genomics offers a comprehensive spatial transcriptomics portfolio under the Visium, Xenium, and Atera platforms, providing whole transcriptome spatial discovery at single cell scale. The Visium Spatial platform uses probe-based (HD WT Panel) or 3' capture-based (HD 3') chemistries with CytAssist instrumentation for FFPE and fresh frozen tissue. The Xenium In Situ platform delivers high-resolution spatial imaging with the Xenium Analyzer (up to 5,000 genes, 472 mm² per run) plus customizable panels and protein subpanels for multiomic analysis. The Atera In Situ platform provides scalable throughput (up to 800 samples/year) at whole-transcriptome scale. Supporting these core spatial platforms, Chromium Single Cell enables single cell multiomics, 10x Genomics Cloud provides instrument connectivity and data analysis, and Premium Automation Enablement services support integration with third-party automation systems.

Differentiator

Problem solved

Functional benefit

Brands

• Visium: Spatial assays for whole transcriptome spatial discovery at single cell scale
• Xenium
• Atera
• Chromium
• Premium Automation Enablement (PAE)

Products and services

• Visium Spatial Assays Whole transcriptome spatial discovery platform at single cell scale using either probe-based (HD WT Panel) or 3' poly(A) capture-based (HD 3') chemistry. Compatible with FFPE, fresh frozen, and fixed frozen tissue samples from human, mouse, and rat.
• Visium CytAssist Instrument used with Visium Spatial assays for tissue processing and spatial gene expression analysis, simplifying workflow and expanding sample access for FFPE and fresh frozen tissue.
• Xenium Analyzer State-of-the-art single cell spatial imaging platform that integrates transcript detection workflow, high-resolution imaging, decoding, and onboard data analysis. Analyzes 472 mm² of tissue per run, targeting up to 480 genes in under 3 days or up to 5,000 genes in under 6 days.
• Xenium Panels Ready-to-use and customizable RNA panels using Xenium Prime chemistry, supporting up to 5,000 genes with options for 9 tissue-specific and 2 comprehensive human/mouse panels, plus multiomic analysis capability including protein subpanels. Compatible with FFPE and fresh frozen tissue.
• Atera In Situ Platform Scalable whole transcriptome spatial platform at subcellular resolution. Delivers up to 800 samples per year at whole-transcriptome scale with single cell sensitivity and unmatched throughput.
• Chromium Single Cell Single cell multiomics platform for analysis of thousands of samples and billions of cells, including FFPE samples. Powers research breakthroughs across cancer research, immunology, neuroscience, and developmental biology.
• Premium Automation Enablement (PAE) Service package designed to help automate assay workflows with third-party automation platforms. Includes strategic coordination sessions, automation documentation, remote support, on-site FAS support, and final data review commentary.

Quantifiable outcome

• Up to 800 1 cm² whole transcriptome samples per year with Atera platform
• +2 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability5 records

Feature5 records

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

Emerging players

• Mission Bio: Single cell multiomics platform focused on genomics and proteomics at single cell resolution, with overlapping applications in cancer research and clonal evolution studies where Chromium is also used.
• Singular Genomics: Develops the G4 sequencing platform with applications in spatial and single cell genomics; an emerging NGS platform competitor that could intersect with Visium library preparation and downstream sequencing workflows.

Direct peers

• Standard BioTools (formerly Fluidigm): Offers mass cytometry (Helios/Hyperion) and imaging mass cytometry platforms for single cell and spatial tissue analysis, overlapping with Chromium single cell multiomics in immunology and oncology customer segments.
• Vizgen: Commercializes MERFISH-based spatial transcriptomics technology, a direct in situ imaging competitor to Xenium Analyzer, with overlapping customer base in academic and pharma translational research.
• NanoString Technologies (Bruker Spatial Biology): Operates the GeoMx Digital Spatial Profiler and CosMx SMI platform for spatial transcriptomics, directly competing with Visium, Xenium, and Atera across both sequencing-based and imaging-based spatial workflows. Acquired by Bruker in 2024.
• Akoya Biosciences: Offers the PhenoCycler and PhenoImager spatial biology platforms for multiplex immunofluorescence and spatial phenotyping, overlapping with Visium/Xenium in tumor microenvironment and immunology research segments.

Broad incumbents

• Bio-Rad Laboratories: Provides ddPCR, Droplet Digital PCR, and life science research instruments, with broader reach in genomics workflows that partially overlap with the company's molecular biology instrumentation footprint.
• Illumina: Dominant sequencing platform provider whose NGS instruments underpin downstream Visium and Chromium workflows. A strategic upstream/downstream incumbent rather than a direct spatial transcriptomics competitor, but with capacity to enter the space.
• Bruker Corporation: Acquired NanoString and offers mass-spec-based and spatial biology solutions through its Bruker Spatial Biology division, providing a broad life sciences tools portfolio that increasingly overlaps with the company's spatial transcriptomics offerings.

Others

• 10x Genomics: The parent/operating entity that owns the Spatial Transcriptomics brand and operates the Visium, Xenium, Atera, and Chromium platforms. Listed for context given the conflation evident in the company data; not a true competitive peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/STomics

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spatial Transcriptomics